Back to top

Image: Bigstock

Falling Earnings Estimates Signal Weakness Ahead for Karyopharm Therapeutics (KPTI)

Read MoreHide Full Article

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Karyopharm Therapeutics Inc. (KPTI - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in KPTI.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen five estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of $2.05 a share a month ago to its current level of a loss of $2.83.

Also, for the current quarter, Karyopharm Therapeutics has seen two downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 68 cents a share from a loss of 56 cents over the past 30 days.   

The stock also has seen some pretty dismal trading lately, as the share price has dropped 15.8% in the past month.

Karyopharm Therapeutics Inc. Price and Consensus

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Medical - Drugs industry, you may instead consider a better-ranked stock - BioSpecifics Technologies Corp . The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank stocks here.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Karyopharm Therapeutics Inc. (KPTI) - free report >>

Published in